Biosimilars to Biobetters - the paths forward 2013
16 May, 2013
Stevenage , 英国
Whilst biopharmaceuticals remain a major component of the global therapeutics market, the ever expanding portfolio of products losing patent protection and with increasing healthcare costs remaining a poignant issue, the opportunity for development of competing, follow on biologics remains an attractive proposition for both Biotech and Pharma companies alike. However, as these biosimilar markets are captured how we manage the life cycle of these products and target specific patient and commercial benefits to maximise our product development strategies becomes increasingly important.
This Euroscicon biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place.
Who should attend
Specialists in regulatory strategy and affairs, Biopharmaceutical developers/manufacturers including analytics/characterisation, marketing professionals, product enabling technology development companies
This Euroscicon biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place.
Who should attend
Specialists in regulatory strategy and affairs, Biopharmaceutical developers/manufacturers including analytics/characterisation, marketing professionals, product enabling technology development companies
场馆
Location: The Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst campus is a unique bioscience community created to provide small biotech and life sciences companies and start-ups with access to the expertise, networks and scientific..
相关活动
Biosimilars to Biobetters - the paths forward 16 May, 2013